Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Syneos Health US, Inc., a leading biopharmaceutical solutions organisation, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2018 through the merger of INC Research and inVentiv Health, the company has quickly established itself in the clinical research and commercialisation sectors.
Specialising in integrated biopharmaceutical solutions, Syneos Health offers a unique combination of clinical development and commercial services, enabling clients to accelerate the delivery of innovative therapies to market. Their commitment to a patient-centric approach and advanced technology sets them apart in a competitive landscape.
With a strong market position, Syneos Health has achieved notable milestones, including recognition for its innovative strategies in clinical trial management and patient engagement. The company continues to drive advancements in the healthcare industry, making significant contributions to the success of its partners.
+19 vs industry average
Syneos Health US, Inc.’s score of 61 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Syneos Health US, Inc. yet.
Syneos Health US, Inc. currently does not have available carbon emissions data for the most recent year, as indicated by the absence of specific figures. The company is a current subsidiary of Syneos Health, Inc., which may influence its climate commitments and initiatives.
Despite the lack of specific emissions data, Syneos Health US, Inc. is part of a broader corporate strategy that includes commitments to climate action. The company is aligned with initiatives from its parent organisation, Syneos Health, Inc., which may include targets set through frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements have not been disclosed.
As a participant in these initiatives, Syneos Health US, Inc. is expected to engage in efforts to reduce its carbon footprint and contribute to global climate goals, although detailed metrics and timelines remain unspecified. The absence of emissions data highlights the need for transparency and accountability in corporate climate strategies.
No climate goals have been disclosed for Syneos Health US, Inc. yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Syneos Health US, Inc. yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more